Welcome to our dedicated page for Todos Med news (Ticker: TOMDF), a resource for investors and traders seeking the latest updates and insights on Todos Med stock.
Todos Medical Ltd. (OTC: TOMDF) pioneers advanced diagnostic solutions through its proprietary TBIA technology, focusing on early cancer detection and Long COVID management. This comprehensive news hub provides investors and medical professionals with verified updates on breakthrough developments in blood-based cancer screening, COVID-19 testing innovations, and therapeutic advancements.
Access timely announcements regarding TMB-1/TMB-2 cancer tests, strategic initiatives from the Provista Diagnostics acquisition, and progress in Tollovid® immune support products. Our curated news collection covers essential updates including regulatory milestones, clinical research findings, and partnership agreements that shape the company's trajectory in precision diagnostics.
Key areas of focus: Cancer detection technologies • Long COVID diagnostic panels • PCR testing advancements • Corporate strategic developments. Bookmark this page for direct access to primary source materials and official press releases, ensuring you remain informed about critical updates impacting diagnostic medicine and shareholder value.
Todos Medical (OTCQB: TOMDF) has received a new Certificate of Free Sale from the FDA for its dietary supplement, Tollovid, permitting a dosing regimen of 60 pills over five days. This regimen aims to support immune function, particularly against coronaviruses. The company plans a direct-to-consumer launch via MyTollovid.com and intends to use a portion of a recent $3.3 million investment from Yozma Group to support this launch. Todos has raised a total of $9.7 million in this financing round, which will also fund ongoing clinical trials.
Todos Medical (OTCQB: TOMDF) has acquired Provista Diagnostics for $7.5 million, enhancing its position in the diagnostics market. Provista operates a lab in Georgia specializing in the Videssa breast cancer blood test and COVID-19 PCR testing. Videssa aims to reduce unnecessary biopsies in the $7.19 billion mammogram naïve market. The acquisition enables Todos to expand COVID-19 testing capabilities and leverage its TBIA platform for cancer diagnostics. Immediate goals include increasing COVID-19 test processing capacity and validating new assays, strengthening Todos' foothold in the diagnostics sector.
Todos Medical announced the initiation of a randomized, double-blind, placebo-controlled Phase 2 clinical trial for its antiviral NLC-V-01 (Tollovir) targeting COVID-19. Conducted at Shaare Zedek Medical Center in Jerusalem, this trial aims to assess the drug's safety and efficacy in hospitalized patients. The primary endpoints include hospital discharge time and clinical improvement. Additionally, data from a previous Phase 1b trial supports the drug's dose selection. The proprietary TolloTest™ will be included as a biomarker to evaluate viral load and contagiousness.
Todos Medical, Ltd. (OTCQB: TOMDF) announced it has received a notice of allowance for a patent from the European Patent Office for its Total Biochemical Infrared Analysis (TBIA) method, which differentiates between benign and malignant tumors using blood samples. The TBIA technology targets early cancer detection, initially focusing on breast and colon cancers. With strategic partnerships in Singapore and Israel, the company aims to commercialize TBIA globally. The technology is expected to compete effectively with liquid biopsy methods in cancer screening.
Todos Medical has announced the successful installation of automated lab equipment at Meadowlands Diagnostics, enhancing capacity to 6,000 PCR tests per day with potential expansion to 12,000 tests. The automation aims to support contracts with skilled nursing facilities and first responders. The company anticipates a progressive increase in sales from this client in the second half of 2021. Todos Medical is focused on diagnostics for COVID-19, cancer, and Alzheimer’s, with ongoing development in innovative testing technologies.
Todos Medical, Ltd. (OTCQB: TOMDF) announced a distribution partnership with Osang Healthcare to distribute the GeneFinder™ COVID-19 Plus RealAMP Kit in the U.S. The kit has received Emergency Use Authorization (EUA) from the FDA and is designed to detect various SARS-CoV-2 variants. Todos Medical plans to make GeneFinder Plus the primary kit for its automated COVID-19 PCR testing labs. The partnership aims to enhance testing capabilities, addressing the need for sensitive tests as the U.S. reopens.
Todos Medical (OTCQB: TOMDF) has successfully installed an automation solution in a Brooklyn lab, boosting its PCR testing capacity from 500 to 6,000 tests per day, with potential expansion to 12,000 tests. This upgrade supports a new contract with the State of Kentucky for nursing home testing. Future pooling could increase capacity to over 40,000 tests daily. The company remains focused on enhancing testing capabilities amid ongoing COVID-19 surveillance needs.
Todos Medical (OTCQB: TOMDF) has announced a new automation and reagent supply agreement with MAJL Diagnostics to enhance COVID-19 PCR testing capabilities. The agreement allows MAJL to process approximately 1,500 PCR tests per day using Todos' automation technology, which includes Tecan liquid handlers and RNA extraction machines. This partnership aims to increase MAJL's testing capacity and facilitate engagement with larger opportunities, particularly in the Atlanta area. Todos is focused on expanding its testing solutions and overall market presence.
Todos Medical, Ltd. (OTCQB: TOMDF) reported significant advancements in its COVID-19 PCR lab testing services as the U.S. prepares for serial testing programs. The company is expanding its molecular lab offerings and preparing for genomic sequencing to address emerging COVID-19 variants. Todos aims to create high-capacity mobile labs capable of conducting over 3,000 tests daily. Financially, the company achieved sales of $5.2M and $7.2M in January and February 2021, respectively, while retiring $3.2M in convertible notes, strengthening its balance sheet for a potential national exchange listing.
Todos Medical (OTCQB: TOMDF) announced $7.15 million in sales for February 2021, a 38.1% increase from January's $5.18 million. This growth is attributed to a new client in the NYC Tri-State Area focusing on COVID-19 testing for schools. The company is optimizing its PCR testing business and expects an additional client to begin operations soon. Todos aims to enhance its COVID-19 product offerings and continue developments in cancer and Alzheimer’s disease diagnostics. The passage of the American Recovery Act is anticipated to support large-scale testing efforts.
